MaxCyte to Buy Akron BioProducts for $151.8 Million
MaxCyte agreed to buy Akron BioProducts from Arcline Investment Management for $151.8 million.
Related stories
Blackstone to Buy Over 15% Stake in IIFL Finance
Blackstone will acquire an over 15% stake in IIFL Finance through a preferential securities issue worth up to 64.14 billion rupees ($682.87 million), the company said.
M impact | MNA | Nov 10, 2026, 11:11 AM UTC
MaxCyte Reports Third-Quarter 2026 Results, Updates Revenue Guidance
MaxCyte reported third-quarter 2026 financial results and updated its full-year 2026 total revenue guidance.
M impact | EQUITY | Nov 10, 2026, 11:07 AM UTC
Globa Terra Acquisition Agrees to Combine With Nature’s Ledger at $323.8 Million Pre-Money Equity Value
Globa Terra Acquisition signed a definitive business combination agreement with Nature’s Ledger at an indicated pre-money equity value of approximately $323.8 million.
M impact | MNA | Nov 10, 2026, 11:03 AM UTC
MaxCyte to Acquire Akron Bio, Expects to Nearly Double Revenue Base
MaxCyte says the acquisition will expand its cell therapy manufacturing offerings and expects to nearly double its revenue base.
M impact | EQUITY | Nov 10, 2026, 11:02 AM UTC
MaxCyte Reports Q3 Adjusted EBITDA of -$5.1 Million
MaxCyte reported Q3 net income of -$4.8 million. Adjusted EBITDA was -$5.1 million versus an IBES estimate of -$7.99 million.
M impact | EARNINGS | Nov 10, 2026, 11:02 AM UTC
NewMed in Talks to Buy 60% Stake in Venezuelan Oil Firm
NewMed Energy said in a regulatory filing that it is examining South American oil assets, starting with a stake in an unnamed company holding Venezuelan onshore oil rights and prod
L impact | MNA | Nov 10, 2026, 10:37 AM UTC